ClinicalTrials.gov
ClinicalTrials.gov Menu

Expanded Access Protocol for PV-10 for Cutaneous or Subcutaneous Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01260779
Recruitment Status : No longer available
First Posted : December 15, 2010
Last Update Posted : July 11, 2016
Sponsor:
Information provided by (Responsible Party):
Provectus Pharmaceuticals ( Provectus Biopharmaceuticals, Inc. )

December 13, 2010
December 15, 2010
July 11, 2016
 
Expanded Access Protocol for PV-10 for Cutaneous or Subcutaneous Tumors
This compassionate use protocol provides expanded access for investigational use of PV-10 in cancer patients who are not eligible for an existing PV-10 clinical trial, for whom there is no comparable or satisfactory approved alternative therapy and whom, in the opinion of the investigator, may benefit from PV-10 administration.
Not Provided
Expanded Access
Drug: PV-10 (10% rose bengal disodium)
Intralesional injection for chemoablation of cutaneous or subcutaneous lesions
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
No longer available
Contact information is only displayed when the study is recruiting subjects
Australia,   United States
 
 
NCT01260779
Provectus Pharmaceuticals ( Provectus Biopharmaceuticals, Inc. )
Provectus Biopharmaceuticals, Inc.
Not Provided
Not Provided
Provectus Pharmaceuticals
July 2016